BilalOmerMD

Pediatric Hematology & Oncology • Houston, TX

Clinical Postdoc Fellow, Pediatric Hematology & Oncology, Baylor College of Medicine

Join to view full profile

Dr. Omer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Omer's full profile

Already have an account?

Office
6701 Fannin St
Tch Children's Cancer Center Cc 1510.00
Houston, TX 77030
Phone+1 832-822-4242

Fax+1 832-825-1453

Education & Training

Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 2010 - 2013
Yale-New Haven Medical CenterResidency, Internal Medicine/Pediatrics, 2005 - 2009
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2005

Certifications & Licensure

TX State Medical License 2013 - 2025
CT State Medical License 2008 - 2010
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant Start of enrollment: 2014 Jun 01
Completed
Not Applicable
Most Closely Human Leukocyte Antigen (HLA)-Matched CMV-specific T Lymphocytes (Viralym-C) Start of enrollment: 2015 Sep 01
Completed
Phase 1
Administration of Donor MultiTAA-Specific T Cells for ALL Start of enrollment: 2016 Feb 01
Active, not recruiting
Phase 1
C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) Start of enrollment: 2019 Apr 23
Active, not recruiting
Phase 1
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) Start of enrollment: 2020 Feb 03
Recruiting
Phase 1
EBV Specific T-Lymphocytes for Treatment of EBV-Positive Lymphoma Start of enrollment: 2022 Oct 31
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

174 citations
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors.
Robin Parihar, Charlotte H. Rivas, Mai Huynh, Bilal Omer, Natalia Lapteva
Cancer Immunology Research. 2019-01-16
11 citations
Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells
Bilal Omer, Paul Castillo, Haruko Tashiro, Thomas Shum, Mai T A Huynh
Frontiers in Medicine. 2018-12-11
66 citations
Vaccination Targeting Native Receptors to Enhance the Function and Proliferation of Chimeric Antigen Receptor (CAR)-Modified T Cells
Miyuki Tanaka, Haruko Tashiro, Bilal Omer, Natasha Lapteva, Jun Ando
Clinical Cancer Research. 2017-07-15

Abstracts/Posters

CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity
Bilal Omer, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Myeloablative Conditioning with Alemtuzumab in Matched Related Donor Hematopoietic Cell Transplant for Sickle Cell Disease Prevents Graft-Versus-Host Disease without C...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Baylor College of Medicine Receives More Than $17 Million from CPRITAugust 21st, 2024
Off-the-Shelf T-cell Therapy Effective Against Viral Infections After Allo-HCTJanuary 13th, 2023
T-cell Therapy Fights Viral Infections Following Stem Cell TransplantsJanuary 13th, 2023
Join now to see all

Other Languages

German